| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Operating Activities | ||||||
Net Income (Loss) Attributable to Parent | ||||||
-58,859 | 63,087 | 114,205 | -193,420 | -105,717 | -116,772 | -51,145 |
Adjustments to reconcile net loss to net cash used in operating activities | ||||||
Depreciation and other expense | ||||||
162 | 183 | 2,800 | 800 | 698 | 127 | 20 |
Amortization of debt issuance costs | ||||||
- | - | - | - | - | - | 88 |
Accretion of debt discount | ||||||
- | - | - | - | - | - | 87 |
Amortization of premium and discounts on investment securities | ||||||
0 | 0 | -140 | -595 | -2,846 | -2,024 | - |
Non-cash charge on acquired in-process research and development | ||||||
0 | 5,619 | 0 | 0 | - | - | - |
Gain on sale of property and equipment | ||||||
150 | 0 | 0 | - | - | - | - |
Gain On Extinguishment Of Royalty Liability | ||||||
0 | 125,000 | 0 | 0 | - | - | - |
Gain on sale of marketable securities | ||||||
- | - | - | - | 57 | 0 | - |
Non-cash change in fair value of warrant liability | ||||||
- | - | - | - | - | - | 1,181 |
Loss on extinguishment of debt | ||||||
- | - | - | - | - | - | -1,091 |
Deferred income taxes | ||||||
0 | 0 | -3,366 | 22,954 | -17,341 | -214 | - |
Share-based compensation | ||||||
9,180 | 11,072 | 18,171 | 31,660 | 24,760 | 13,040 | 2,871 |
Stock-based consideration in connection with license acquisition | ||||||
85 | 0 | 0 | - | - | - | - |
Excess tax benefits from share-based compensation | ||||||
- | - | - | - | 1,302 | 4,256 | - |
Changes in operating assets and liabilities: | ||||||
Due from Novartis Pharma AG | ||||||
- | - | - | - | 3,429 | 960 | - |
Income tax receivable | ||||||
-1,765 | -1,387 | 1,387 | -3,421 | -48 | - | - |
Due from Novartis Pharma AG | ||||||
0 | 0 | -3,531 | -858 | - | - | - |
Prepaid expense and other assets | ||||||
-45 | -1,070 | -370 | 995 | -3,260 | 2,008 | 6,761 |
Accrued interest receivable | ||||||
0 | 0 | -466 | -203 | -155 | -280 | - |
Other assets | ||||||
- | - | - | -27 | 107 | 127 | 96 |
Accrued research and development expenses | ||||||
-477 | 2,353 | -42,256 | 28,420 | 10,902 | 5,433 | 1,472 |
Accounts payable and accrued expenses | ||||||
-241 | -1,682 | -4,481 | 14 | 3,311 | 4,897 | 2,417 |
Deferred revenue | ||||||
0 | 0 | -209,977 | -3,090 | - | - | - |
Deferred revenue | ||||||
- | - | - | - | 3,442 | 209,624 | - |
Net cash used in operating activities | ||||||
-48,490 | -41,911 | -121,821 | -108,596 | -78,531 | - | - |
Net cash used in operating activities | ||||||
- | - | - | - | - | 111,088 | -48,775 |
Investing Activities | ||||||
Purchase of marketable securities | ||||||
0 | 0 | 12,014 | 72,197 | 411,565 | 597,762 | - |
Sale of marketable securities | ||||||
- | - | - | - | 395,977 | 0 | - |
Maturities of marketable securities | ||||||
0 | 0 | 166,806 | 86,500 | 266,000 | 171,600 | - |
Purchase of property and equipment | ||||||
- | - | - | 572 | 2,615 | 1,655 | 5 |
Proceeds from sale of assets | ||||||
150 | - | 0 | - | 6 | 0 | - |
Net cash provided by (used in) investing activities | ||||||
150 | 0 | 154,792 | 13,731 | 247,803 | - | - |
Net cash provided by (used in) investing activities | ||||||
- | - | - | - | - | -427,817 | -5 |
Financing Activities | ||||||
Proceeds from issuance of common stock and pre-funded warrants, net | ||||||
- | - | - | 0 | - | - | - |
Payment of debt issuance costs | ||||||
- | - | - | - | - | - | 43 |
Proceeds from employee stock plan purchases | ||||||
273 | 65 | 71 | 6,934 | 11,473 | 2,949 | 94 |
Proceeds from follow-on public offering, net | ||||||
- | - | - | - | - | 55,409 | - |
Proceeds from initial public offering, net | ||||||
- | - | - | - | - | - | 175,555 |
Excess tax benefits from share-based compensation | ||||||
- | - | - | - | 1,302 | 4,256 | - |
Net cash provided by financing activities | ||||||
42,838 | 6,140 | 71 | 6,934 | 12,775 | - | - |
Net change in cash and cash equivalents | ||||||
-5,502 | -35,771 | 33,042 | - | - | - | - |
Net change in cash and cash equivalents | ||||||
- | - | - | -87,931 | 182,047 | - | - |
Repayment of venture debt facility, net | ||||||
- | - | - | - | - | - | -11,900 |
Proceeds from issuance of preferred stock, net | ||||||
- | - | - | - | - | - | 49,699 |
Proceeds from royalty purchase agreement | ||||||
- | - | - | - | - | 83,333 | 41,667 |
Net cash provided by financing activities | ||||||
- | - | - | - | - | 145,947 | 255,072 |
Net change in cash and cash equivalents | ||||||
- | - | - | - | - | -170,782 | 206,292 |
Supplemental disclosure of cash paid | ||||||
Income taxes received, net | ||||||
-1,893 | -2,467 | -245 | -26,998 | 399 | 40,159 | - |
Interest | ||||||
- | - | - | - | - | - | 1,523 |
Supplemental disclosures of non-cash information related to investing activities | ||||||
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax | ||||||
0 | 0 | 212 | 261 | - | - | - |
Common stock issued to acquire net assets of Inception 4, Inc. | ||||||
0 | 11,694 | 0 | 0 | - | - | - |
Operating right-of-use assets obtained in exchange for lease obligations | ||||||
1,469 | - | - | - | - | - | - |
Change in unrealized loss on available for sale securities, net of tax | ||||||
- | - | - | - | -408 | -65 | - |
Conversion of preferred stock to common stock upon completion of IPO | ||||||
- | - | - | - | - | - | 174,310 |
Accreted dividends on Series A, Series A-1, Series of B, B-1 and Series C Preferred Stock | ||||||
- | - | - | - | - | - | 5,891 |
Inception 4 | ||||||
Proceeds from issuance of common stock and pre-funded warrants, net | ||||||
0 | 6,075 | 0 | - | - | - | - |
Public Stock Offering | ||||||
Proceeds from issuance of common stock and pre-funded warrants, net | ||||||
42,565 | 0 | 0 | - | - | - | - |